Renovo, plc.

Infobox_Company
company_name = Renovo, plc.
company_
company_type = Public (lse|RNVO)
company_slogan =
foundation = October 2000
location = flagicon|UK Manchester, UK
key_people = Mark Ferguson (CEO)
Sharon O'Kane
num_employees =
industry = Biotechnology
products = 4 in clinical development
homepage = [http://www.renovo.com www.renovo.com]
revenue =
net_income =

Renovo, plc. (lse|RNVO) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research [ [http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html London Regenerative Medicine Network - January 2007 Meeting] ] , and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" [ [http://www.renovo.com Renovo - Home Page] ] in 2009.

The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes [ [http://www.renovo.com/content.asp?c_id=15 Renovo - Business Strategy] ] .

Products

Currently the company doesn't have a marketed product, though its pipeline includes one drug in phase III clinical development, three drugs in phase II clinical development, and numerous pre-clinical candidates.

References

External links

* [http://www.renovo.com www.renovo.com]